caa a22 4500 606158383 CHVBK 20210128100619.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10557-015-6627-0 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6627-0 Altered microRNome Profiling in Statin-Induced HepG2 Cells: A Pilot Study Identifying Potential new Biomarkers Involved in Lipid-Lowering Treatment [Elektronische Daten] [Tomás Zambrano, Rosario Hirata, Mario Hirata, Álvaro Cerda, Luis Salazar] Purpose: Statins are widely prescribed drugs to manage hypercholesterolemia. Despite they are considered effective lipid-lowering agents, significant inter-individual variability has been reported in relation to drug response. Among the reasons explaining this variation, genetic factors are known to partially contribute. Nonetheless, poor evidence exists regarding epigenetic factors involved. Methods: We investigated if atorvastatin can modulate the cholesterol related miR-33 family. Furthermore, we analyzed the microRNA expression profiles in HepG2 cells treated for 24hours with atorvastatin or simvastatin using a microarray platform. Results: Our results indicate that atorvastatin does not influence the expression of the miR-33 family. In addition, microarray examination revealed that atorvastatin modulated thirteen miRs, whilst simvastatin only affected two miRs. All significantly modulated miRs after simvastastin therapy were also modulated by atorvastatin. In addition, four novel miRs with previously unreported functions were identified as statin-modulated. Conclusion: We identified several novel miRs affected by statin treatment. Additional research is needed to determine the biological significance of differentially expressed miRs identified in statins-induced HepG2 cells. Springer Science+Business Media New York, 2015 Statins nationallicence miRNAs nationallicence Epigenetics nationallicence HepG2 nationallicence Pharmacoepigenetics nationallicence Cholesterol nationallicence Zambrano Tomás Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut Hirata Rosario School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil aut Hirata Mario School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil aut Cerda Álvaro Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut Salazar Luis Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 509-518 0920-3206 29:6<509 2015 29 10557 https://doi.org/10.1007/s10557-015-6627-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6627-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zambrano Tomás Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut NATIONALLICENCE 700 1- Hirata Rosario School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil aut NATIONALLICENCE 700 1- Hirata Mario School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil aut NATIONALLICENCE 700 1- Cerda Álvaro Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut NATIONALLICENCE 700 1- Salazar Luis Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 509-518 0920-3206 29:6<509 2015 29 10557